REG - Ondine Biomedical - Mölnlycke® and Ondine Join Forces Against HAIs

Ondine BiomedicalAnnouncement

23/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240923:nRSW1379Fa&default-theme=true

RNS Number : 1379F  Ondine Biomedical Inc.  23 September 2024

This Announcement contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as it forms part of UK law by
virtue of the European Union (Withdrawal) Act 2018 as amended. Upon the
publication of this Announcement, this inside information is now considered to
be in the public domain.

 

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Mölnlycke(®) and Ondine Join Forces Against HAIs

 

Mölnlycke Health Care partners with Ondine for Steriwave distribution
collaboration in the key markets of the UK, Europe and the Middle East

 

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, and Mölnlycke Health Care
(Gothenburg Sweden), a world-leading MedTech company that specializes in
innovative solutions for wound care and surgical procedures, are pleased to
announce a strategic partnership to bring Ondine's Steriwave(®) nasal
decolonization technology to the United Kingdom, EU, and Middle East markets.

 

This collaboration marks a significant milestone in the fight against
healthcare-associated infections (HAIs) and the growing threat of
antimicrobial resistance (AMR), as Steriwave safely reduces hospital
infections without generating AMR. Steriwave, a non-antibiotic,
light-activated nasal decolonization therapy, has been clinically proven( 1 
(#_edn1) )( 2  (#_edn2) )( 3  (#_edn3) )(-( 4  (#_edn4) ))( 5  (#_edn5) ) to
reduce harmful pathogens in the nasal passages, a common source of HAIs and
cause of higher rates of mortality, length of stay and readmissions.
Mölnlycke's established distribution networks, strong brand and market
presence in over 100 countries make it an ideal partner to accelerate the
adoption of Steriwave.

 

The first market focus starting later this year, is the pivotal UK market
where Steriwave is already deployed several National Health Service (NHS)
Trusts, including, Mid Yorkshire Teaching NHS Trust and Leeds Teaching
Hospital NHS Trust.  Steriwave is also listed with NHS Supply Chain, a
national body that manages the sourcing, delivery and supply of healthcare
products to the NHS and healthcare organizations in England and Wales. The UK
market, with a total addressable market of over 3 million major surgeries
annually(( 6  (#_edn6) )) and over 200,000 annual intensive care unit (ICU)
admissions, 7  (#_edn7) has significant global influence in setting best
practice for patient care.

 

Mölnlycke(®) will incorporate Steriwave as a key product in its infection
control portfolio, enhancing its product offerings with a focus on preventing
HAIs and reducing AMR. Distribution will commence in the UK in Q4 2024,
followed by expansion into the EU and Middle East regions in 2025, leveraging
Mölnlycke's extensive market presence to ultimately broaden the impact of
this innovative technology on a global scale. Mölnlycke will spearhead sales
and marketing efforts across the UK, EU, and Middle East.

 

Lina Karlsson, Executive Vice President Antiseptics, Mölnlycke, stated:
"Mölnlycke's purpose is to revolutionize care for people and planet. In the
Antiseptics business area, we do this by making patient skin decolonization
manageable and motivational. We believe that Steriwave can improve the lives
of millions of people, fitting perfectly with our purpose and mission. The
ability to rapidly eliminate multiple drug-resistant pathogens without
generating antimicrobial resistance is key to our sustainability initiative,
and complements our Hibiwash(®) brand skin prep line, enabling us to provide
comprehensive 'nose-to-toes' decolonization prior to surgery. Universal
decolonization is now a well-accepted practice to improve surgical outcomes
and produce significant cost savings to healthcare systems."

 

Carolyn Cross, CEO of Ondine Biomedical, commented: "We are excited to be
partnering with Mölnlycke Health Care, whose global reach, corporate vision
and commitment to sustainable healthcare aligns perfectly with our own core
values, purpose and mission. The Mölnlycke collaboration represents a
transformative step towards our ambitious plans to combat HAIs and
antimicrobial resistance globally.  We look forward to working with
Mölnlycke in these initial key markets and beyond."

 

HAIs remain a critical challenge across the world, consuming approximately 6%
of European public sector budgets( 8  (#_edn8) ) and resulting in significant
costs, avoidable deaths, and human suffering. Post-surgical infections, in
particular, extend recovery times and often require prolonged antibiotic
treatment, something the UK government is actively seeking to reduce as part
of its 5-year action plan for antimicrobial resistance
(https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029)
, published in May 2024.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections,( 9  (#_edn9) ) and the Society for
Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023,
recommend nasal decolonization for major surgical procedures.( 10  (#_edn10) )

 

Steriwave uses a patented light-activated agent to rapidly eliminate
infection-causing pathogens in a single, 5-minute treatment. The process works
so rapidly that pathogens do not have the opportunity to develop
resistance, 11  (#_edn11) making it an effective alternative to antibiotics.
Hospitals using Steriwave have reported high levels of staff and patient
compliance. Steriwave has also been proven to be highly effective against
drug-resistant pathogens. A 2023 study
(https://ondinebio.com/steriwave-proven-highly-effective-against-xdr-bacteria/)
showed that Steriwave is highly effective (>99.99% kills in 20 seconds)
against both moderately drug-resistant (MDR) and extensively drug-resistant
(XDR) pathogens.

 

-Ends-

 

About Mölnlycke Health Care

Mölnlycke Health Care is a world-leading MedTech company that specializes in
innovative solutions for wound care and surgical procedures. Mölnlycke
products and solutions are used daily by hospitals, health care providers and
patients in over 100 countries around the world. Founded in 1849, Mölnlycke
is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
(https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.molnlycke.com%2F&data=05%7C01%7CCaroline.Strom%40molnlycke.com%7C2ac90538d0f74e1666b808dbd628f64d%7C4d3f6608ec8c4b1f9484274a4b699efb%7C1%7C0%7C638339243641321648%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=aQic0IwefykdY8uK9y43B%2F7mL5lnfm6Yi77%2Fu8p7Osc%3D&reserved=0)

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader
innovating light-activated antimicrobial therapies (also known as
'photodisinfection'). In addition to Steriwave, Ondine has a pipeline of
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name
Steriwave(®). In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

About Steriwave(®)

Ondine's Steriwave nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an
easy-to-use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach - unlike antibiotics, which have
resistance rates reported as high as 81%([ (#_edn12) )(12] (#_edn12) ) (-) is
that pathogens do not develop resistance to the therapy.

 

Enquiries:

 

 Ondine Biomedical Inc.
 Angelika Vance, Vice President of Corporate Communications         +001 604 838 2702

 Mölnlycke Health Care
 Mathilda Blomsterberg, Global Communications Manager Antiseptics  +46 737 73 38 14

 Singer Capital Markets (Nominated Adviser, Joint Broker)
 Phil Davies, Sam Butcher                                           +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                                     +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact for Ondine Biomedial)         +44 (0)77 1000 5910
 Simon Vane Percy, Amanda Bernard

 

 1  (#_ednref1) Bryce E, Wong T, Forrester L, et al. Nasal photodisinfection
and chlorhexidine wipes decrease surgical site infections: a historical
control study and propensity analysis [published correction appears in J Hosp
Infect. 2015 Sep;91(1):93]. J Hosp Infect. 2014;88(2):89-95. (link
(https://pubmed.ncbi.nlm.nih.gov/25171975/) )

 2  (#_ednref2) Moskven E, Banaszek D, Sayre EC, et al. Effectiveness of
prophylactic intranasal photodynamic disinfection therapy and chlorhexidine
gluconate body wipes for surgical site infection prophylaxis in adult spine
surgery. Can J Surg. 2023;66(6):E550-E560. (link
(https://www.canjsurg.ca/content/66/6/E550) )

 3  (#_ednref3) Ondine Biomedical's nasal photodisinfection cuts surgical site
infections by 66%. Press release 18 April 2023 (link
(https://ondinebio.com/ondine-biomedicals-nasal-photodisinfection-cuts-surgical-site-infections-by-66/)
)

 4  (#_ednref4) Pre-op Nasal Decolonization via Photodisinfection: A Pilot
Study in Spinal Surgery Procedures at the Ottawa Hospital. Poster presentation
at IPAC Canada 2023 National Conference. (link
(https://ipac-canada.org/photos/custom/conf/23conf/posters/Poster_M47.pdf) )

 5  (#_ednref5) Street C, Pedigo L, Gibbs A, et al. Antimicrobial photodynamic
therapy for the decolonization of methicillin-resistant Staphylococcus aureus
from the anterior nares. In: Kessel DH, editor. Photodynamic therapy: back to
the future. 12th World Congress of the International Photodynamic Association.
Vol. 7380 of Proceedings series. Bellingham (WA): SPIE; 2009. (link
(https://www.spiedigitallibrary.org/conference-proceedings-of-spie/7380/73803B/Antimicrobial-photodynamic-therapy-for-the-decolonization-of-methicillin-resistant-Staphylococcus/10.1117/12.828279.short#_=_)
)

 6  (#_ednref6) Surgical Procedure Volumes in UK from 2021-2029. Life Science
Intelligence; 2023 Jan. Volume 23.

 7  (#_ednref7) Hospital Admitted Patient Care Activity, 2011-22. Secondary
Care Analytical Team, NHS Digital. Health and Social Care Information Centre.
22 Sep 2022. (link
(https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2021-22)
)

(( 8  (#_ednref8) )) OECD/European Union (2020), Health at a Glance: Europe
2020: State of Health in the EU Cycle, OECD Publishing, Paris. (link
(https://doi.org/10.1787/82129230-en) )

(( 9  (#_ednref9) )) Surgical Site Infection Prevention: Key facts on
decolonization of nasal carriers of Staphylococcus aureus. World Health
Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

(( 10  (#_ednref10) )) Calderwood MS, Anderson DJ, Bratzler DW, et al.
Strategies to prevent surgical site infections in acute-care hospitals: 2022
Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

 11  (#_ednref11) Pedigo LA, Gibbs AJ, Scott RJ, et al. Absence of bacterial
resistance following repeat exposure to photodynamic therapy. Proc. SPIE 7380,
Photodynamic Therapy: Back to the Future, 73803H (2009). (link
(https://www.spiedigitallibrary.org/conference-proceedings-of-spie/7380/73803H/Absence-of-bacterial-resistance-following-repeat-exposure-to-photodynamic-therapy/10.1117/12.822834.short?SSO=1#_=_)
)

 12  (#_ednref12) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin
resistance: clinical implications and potential alternatives for the
eradication of MRSA. J Antimicrob Chemother. 2015;70(10):2681-2692. (link
(https://academic.oup.com/jac/article/70/10/2681/829798?login=false) )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSEAFWEELSEFU